0000000001190086

AUTHOR

F Liu

showing 4 related works from this author

Measurement of Semileptonic B Decays into Orbitally Excited Charmed Mesons

2009

We present a study of B decays into semileptonic final states containing charged and neutral D-1(2420) and D-2*(2460). The analysis is based on a data sample of 208 fb(-1) collected at the Y(4S) resonance with the BABAR detector at the PEP-II asymmetric-energy B factory at SLAC. With a simultaneous fit to four different decay chains, the semileptonic branching fractions are extracted from measurements of the mass difference Delta m = m(D**) - m(D) distribution. Product branching fractions are determined to be B(B+ -> D(1)(0)l(+)nu(l)) x B(D-1(0) -> D*+pi(-)) = (2.97 +/- 0.17 +/- 0.17) x 10(-3), B(B+ -> D-2*l(+)nu(e)) x B(D-2*(0) -> D(*)+pi(-)) = (2.29 +/- 0.23 +/- 0.21) x 10(-3), B(B-0 -> D…

Semileptonic decayParticle physicsMesonBABARHadronAnalytical chemistryGeneral Physics and AstronomyFOS: Physical sciencesB meson01 natural sciencesPARTICLE PHYSICS; PEP2; BABARHigh Energy Physics - ExperimentParticle decayHigh Energy Physics - Experiment (hep-ex)Pion0103 physical sciencesPEP2[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]B meson010306 general physicsB meson; CP violationPhysics010308 nuclear & particles physicsBranching fractionParticle physicsBABAR detectorHEPB-factoryCP violationBaBarPARTICLE PHYSICSFísica de partículesExperimentsPHYSICAL REVIEW LETTERS
researchProduct

Improved limits on the lepton-flavor violating decays tau(-) -> l(-)l(+)l(-)

2007

A search for the neutrinoless, lepton-flavor violating decay of the tau lepton into three charged leptons has been performed using 376fb-1 of data collected at an e+e- center-of-mass energy around 10.58 GeV with the BABAR detector at the SLAC PEP-II storage rings. In all six decay modes considered, the numbers of events found in data are compatible with the background expectations. Upper limits on the branching fractions are set in the range (4-8)×10-8 at 90% confidence level. © 2007 The American Physical Society.

Particle physicsVIOLATIONMesonElectron–positron annihilationCharged particleGeneral Physics and AstronomyElectron01 natural sciencesNuclear physicsParticle decaySEARCH; LEPTON; FLAVOR; VIOLATION; BABAR; SLACPositronSEARCH0103 physical sciencesFree energyLEPTON010306 general physicsPhysicsVolume fractionMuon010308 nuclear & particles physicsBranching fractionHigh Energy Physics::PhenomenologyParticle physicsBABAR detectorLepton flavorCharged leptonHEPGermanium compoundBaBarHigh Energy Physics::ExperimentParticle detectorSLACFísica de partículesExperimentsFLAVORLepton
researchProduct

Measurement of the semileptonic branching fraction of the B_{s} meson

2012

We report a measurement of the inclusive semileptonic branching fraction of the B_s meson using data collected with the BaBar detector in the center-of-mass (CM) energy region above the Upsilon(4S) resonance. We use the inclusive yield of phi mesons and the phi yield in association with a high-momentum lepton to perform a simultaneous measurement of the semileptonic branching fraction and the production rate of B_s mesons relative to all B mesons as a function of CM energy. The inclusive semileptonic branching fraction of the B_s meson is determined to be B(B_s to l nu X)=9.5 (+2.5/-2.0)(stat)(+1.1/-1.9)(syst)%, where l indicates the average of e and mu.

Nuclear and High Energy PhysicsParticle physicssemileptonic branching fractionMesonHigh Energy Physics::Latticesemileptonic branching fraction B_s mesonFOS: Physical sciences01 natural sciencesResonance (particle physics)semileptonic Bs-meson decaysHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Mesons (Nuclear physics)B mesonSDG 7 - Affordable and Clean EnergyMesons (Física nuclear)010306 general physicsNuclear Experiment14.40.Nd 13.20.HePhysics/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energy010308 nuclear & particles physicsBranching fractionLeptons (Física nuclear)High Energy Physics::PhenomenologyBABAR detectorbranching fraction measurementHEPPACS: 14.40.Nd 13.20.HeBaBar detector at SLAC; semileptonic Bs-meson decays; branching fraction measurementLeptons (Nuclear physics)Yield (chemistry)BaBarB_s mesonHigh Energy Physics::ExperimentBaBar detector at SLACsemileptonic Bs-meson decayLeptonProduction rate
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct